iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | BTECRegistrer dig for at låse op for ratings |
Fondens performance | 30-04-2024 |
Vækst af 1.000 (DKK) | Avanceret graf |
Fond | 16,4 | 7,0 | -6,2 | 2,9 | -2,1 | |
+/-Kat | -2,4 | 10,1 | 6,6 | 1,6 | 0,2 | |
+/-Indeks | -8,9 | 0,1 | -3,1 | -7,3 | -10,1 | |
Kategori: Sektor - Bioteknologi, Aktier | ||||||
Kategoribenchmark: Morningstar Gbl Biotechnolo... |
Oversigt | ||
Closing Price 03-05-2024 | USD 6,32 | |
Kursændring 1 dag | 1,41% | |
Morningstar Kategori™ | Sektor - Bioteknologi, Aktier | |
Omsætning | 8329 | |
Børs | LONDON STOCK EXCHANGE, THE | |
ISIN | IE00BYXG2H39 | |
Markedsværdi i alt (mio.) 03-05-2024 | USD 508,15 | |
Seneste TNA(mio.) 03-05-2024 | USD 472,47 | |
Løbende omkostning 18-04-2024 | 0,35% | |
Investeringsstrategi | Passiv |
Investeringsmålsætning: iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | BTEC |
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. |
Returns | |||||||||||||
|
Management | ||
Manager navn Startdato | ||
- - | ||
Startdato 19-10-2017 |
Annonce |
Kategoribenchmark | |
Fondens indeks | Morningstar indeks |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Formuefordeling iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | BTEC | 01-05-2024 |
|
|
Top 5 placeringer | Sektor | % |
Amgen Inc | Healthcare | 8,53 |
Vertex Pharmaceuticals Inc | Healthcare | 8,05 |
Regeneron Pharmaceuticals Inc | Healthcare | 7,88 |
Gilead Sciences Inc | Healthcare | 7,65 |
AstraZeneca PLC ADR | Healthcare | 4,78 |
Øget Mindsket Ny siden sidste portefølje | ||
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | BTEC |